AoXiang Pharmaceuticals: Cooperative product Topotecan Citrate Tablets granted overseas marketing approval

Aoxiang Pharmaceutical Announcement: Recently, its partner STADA Arzneimittel AG’s subsidiary Spirig HealthCare AG received approval from the Swiss Medicines Agency for the marketing of citrate tofacitinib tablets. Citrate tofacitinib tablets are the world’s first approved oral Janus kinase inhibitor, belonging to targeted synthetic disease-modifying anti-rheumatic drugs. It works by inhibiting the intracellular JAK signaling pathway to regulate immune responses and is mainly used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.